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Spatients in the fasting state in an attempt to control for dietary
consumption. In addition, the control group should also be
closely matched to the disease group with regard to age, gen-
der, and so forth. However, we wanted controls to be free of
any possible disease that may confound our results. Given the
typical age and comorbid conditions of patients with esopha-
geal adenocarcinoma, it was exceedingly difficult to find
controls in a similar age group without any comorbid condi-
tions. We also do not have information regarding the proteins
that underwent the detected glycomic changes. This endeavor
will be undertaken once our data have been validated. It
should be noted, however, that the mere identification of
a glycomic ‘‘pattern’’ or ‘‘signature’’ may nonetheless prove
clinically useful even in the absence of the identification of the
specific protein(s).
CONCLUSIONS
We demonstrated the potential of MS-based serum glyco-
mic profiling in the diagnosis of esophageal adenocarcinoma
and its precursor lesions. The data provide some insight into
the mechanisms of altered glycosylation and may thus
indicate structural changes in glycoproteins. Such methodol-
ogies may form the basis for future clinical applications,
such as disease screening or monitoring through the detec-
tion of glycan-specific biomarkers. Further validation and
future prospective studies are needed to confirm the utility
of glycomic profiling.
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Dr A. Pennathur (Pittsburgh, Pa). Dr Hammoud, that was an
excellent presentation and a very interesting study. In your study
you examined the serum samples of 5 patients with BE, 11 patients
with HGD, and 50 patients with esophageal cancer, the majority of
whom had locally advanced or metastatic disease. You identified 26
known glycan structures that were significantly different, and
among these, 8were different in all pairwise comparisons. You con-
cluded that a subset of glycans can be selected as candidate bio-
markers for the differentiation of controls, BE, and esophageal
cancer and that further validation will be necessary. This is an inter-
esting study, and I agree that further validation will definitely be
necessary. One of the difficulties with serum proteomics or profiling
is to standardize the conditions at the time of collection of the sam-
ple.Were these samples obtained in the office or the operating room,
was the patient awake or under anesthesia, and were these samples
handled similarly across the spectrum of all these categories?
Dr Hammoud. They were collected in the clinic. We made sure
that patients were in a fasting state when they came to see us, and
they were all done by the same person in terms of isolating the se-
rum so we could control the protocol.
Dr Pennathur. Excellent. Were these samples from patients
with HGD obtained in patients who had undergone esophagec-
tomy? As you well know, several surgical series have demonstrated
occult cancer in approximately 40% of patients with HGDwho had
undergone esophagectomy. The serum sample from a small sample
size of 11 patients with HGD determined purely by endoscopy may
confound your results.
Dr Hammoud. That is absolutely true. There were 6 patients in
that cohort who underwent surgery and at surgery were docu-
mented and confirmed to have only HGD. The other 5 were endo-
scopic procedures.
Dr Pennathur. Are you planning any longitudinal follow-up in
your patients with BE to determine changes in the profile, and do
we know which proteins are glycosylated?
Dr Hammoud. No, we are not longitudinally following them,
and we have not yet gotten to the point where we’re looking at
the proteins involved.gery c May 2010
Hammoud et al General Thoracic SurgeryDr D. Harpole (Durham, NC). This is fascinating. As a next
step, obviously you could perform MALDI in another set of pa-
tients and see if you come up with the same profile, and you may
or may not. What would be your step in making this a more user-
friendly test? In other words, are you going to try and identify
the proteins through MS/MS and develop a serum enzyme-linked
immunosorbent assay test or something for the glycosylated pro-
teins you have discovered, or do you think this is just exploratory
and you actually want to have a larger patient population and refine
your dataset before you develop a test?
Dr Hammoud. The latter. We definitely need more sample sets.
As you know, even in Pittsburgh and large centers, they only seeThe Journal of Thoracic and Carapproximately 150 of these cases per year. We see approximately
50 to 60 cases per year. So I need several years to collect the spec-
imens and have a large enough pool to refine the data. My ultimate
goal is not really the proteins. I think that’s kind of a Holy Grail,
kind of like looking for the cancer suppressor gene that’s responsi-
ble for something. My ultimate goal is to generate MS profiles, and
if we can identify and correlate a profile that says HGD in a patient
is going to progress to adenocarcinoma, I consider that a clinically
relevant thing to do.
Dr Harpole. A MALDI fingerprint, in other words.
Dr Hammoud. Correct.diovascular Surgery c Volume 139, Number 5 1223
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